Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

Lignende værker

• The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
  af: Tibes, Raoul, et al.
  Udgivet: (2015)
• Bcl‐2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT‐737, ABT‐263 and ABT‐199 by impeding direct binding
  af: Song, Ting, et al.
  Udgivet: (2016)
• Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
  af: Mérino, Delphine, et al.
  Udgivet: (2012)
• BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia
  af: Del Gaizo Moore, Victoria, et al.
  Udgivet: (2008)
• ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
  af: Cang, Shundong, et al.
  Udgivet: (2015)